Sign in
TerminatedPhase 2

The Effects of Suvorexant on Sleep, Stress, and Cue-reactivity in Methamphetamine Use Disorder

Key facts

Who runs it
The University of Texas Health Science Center, Houston
Where
Houston, United StatesSee the site
Trial code
Status
Terminated
Phase
Phase 2
People taking part
7 people enrolled
Started
9 Mar 2023
Ended
28 Mar 2024
Type of study
Interventional, 2 groups
Treatments tested
  • suvorexant (SUVO)
  • Placebo
Record updated
29 April 2025
Why it stopped
Lack of enrollment

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Meet DSM-5 criteria for MA use disorder
  • Be fluent in English and able to understand the consent form

Who cannot take part

  • Are currently taking medications with known drug interactions with SUVO (e.g., MAO inhibitors, anticonvulsants, haloperidol, phenothiazines, anesthetics, and any sedative)
  • Have an alcohol use disorder or report binge drinking (>7 drinks for women and >14 drinks for men)
  • Have a greater than mild substance use disorder on any other illicit substance
  • Have any medical conditions contraindicating SUVO (e.g., severe pulmonary disease, severe cardiovascular disease or clinically abnormal ECG, severe liver or kidney disease, seizure disorder, or sleep disorder - particularly narcolepsy)
  • Have a current DSM-5 psychiatric disorder or neurological disease requiring on-going treatment that would make participation unsafe
  • Have history of seizure disorder
  • Are pregnant or breast feeding
  • BMI > 30 (women only)
  • Have a head injury with loss of consciousness in the last 5 years

Where in United States

  • The University of Texas Health Science Center at HoustonHouston, United States

About the trial

What the trial wants to find out

The purpose of this study is to determine the effects of SUVO on sleep, stress, and cue reactivity/craving and to evaluate the preliminary safety and side effects profile of suvorexant (SUVO)

The 2 groups in the trial

  • 1 week Placebo, then 1 week suvorexant (SUVO)Treatment being tested

    After 1 week of placebo treatment there will be 1 week of wash out period before start of study medication

    Treatment: suvorexant (SUVO) and Placebo

  • 1 week suvorexant (SUVO), then 1 week PlaceboTreatment being tested

    After 1 week of SUVO treatment there will be 1 week of wash out period before start of placebo

    Treatment: suvorexant (SUVO) and Placebo

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Record updated
29 April 2025